ATLANTA–(BUSINESS WIRE)–UPS (NYSE: UPS) today announced that it has completed the acquisition of Frigo-Trans and its sister company BPL, which provide industry-leading, complex healthcare logistics solutions across Europe. The acquisitions further enhance the end-to-end capabilities available to UPS Healthcare customers, who increasingly need temperature-controlled and time-critical logistics solutions globally. Frigo-Trans’ network includes temperature-controlled warehousing ranging from cry

CHARLOTTESVILLE, Va.–(BUSINESS WIRE)–VION Biosciences, a life science platform company focused on specialty materials in the life science research, diagnostics, and drug discovery spaces, today announced Vince Stoyanov as its Chief Strategy and Development Officer. He will lead corporate development, mergers and acquisitions (M&A), and other related corporate functions, bringing both expertise and continued energy to VION at a critical moment in its expansion efforts. With more than 20 ye

BALTIMORE–(BUSINESS WIRE)–Sapio Sciences, la plateforme d’informatique de laboratoire science-aware™, a annoncé aujourd’hui l’obtention de la certification Hébergeur de Données de Santé (HDS), une exigence obligatoire pour les organisations hébergeant des données personnelles de santé en France. L’obtention de la certification HDS souligne la conformité de Sapio Sciences aux normes strictes de sécurité, de confidentialité et de continuité opérationnelle. Cet accomplissement réaffirme l’engage

BALTIMORE–(BUSINESS WIRE)–Sapio Sciences, the science-aware™ lab informatics platform, today announced its achievement of the Hébergeur de Données de Santé (HDS) certification, a mandatory requirement for organizations hosting personal health data in France. Achieving HDS certification underscores Sapio Sciences’ compliance with stringent security, privacy, and operational continuity standards. This accomplishment reaffirms the company’s commitment to safeguarding personal health data and adh

RIYADH, Saudi Arabia–(BUSINESS WIRE)– #Biotechnology–In a landmark step towards advancing cancer care in the Middle East, BOSTON ONCOLOGY ARABIA and SPIMACO have signed a Memorandum of Understanding (MoU) to localize the production of advanced oral oncology treatments in the Kingdom. Announced at the CPHI Middle East conference, this partnership reflects a shared commitment to improving patient outcomes, fostering local expertise, and contributing to Saudi Arabia’s Vision 2030 goals for healthcare transforma

DALLAS–(BUSINESS WIRE)–EoS Fitness, the national High Value. Low Price. (HVLP)® gym brand with more than 175 locations open or on the way, closed out Q4 strong.

WUPPERTAL, Germany–(BUSINESS WIRE)–Aicuris announced today the appointment of Jacques Dumas, Ph.D., as Chief Scientific Officer (CSO), effective January 1, 2025. Dr. Dumas brings over 30 years of experience in pharmaceutical research and development (R&D), with a strong track record of advancing innovative medicines in oncology and infectious diseases from the discovery to launch. In his new role, Dr. Dumas will oversee Aicuris’ R&D efforts, ensuring alignment with the company’s strat

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Mirvie, a company bringing a personalized, predictive, and preventive approach to pregnancy complications, today announced the company was selected to present new research demonstrating the ability of the Mirvie RNA platform to predict the risk of severe fetal growth restriction in pregnancy. The abstract, “Prediction of severely small-for-gestational-age infants using a novel cell-free RNA model,” will be presented on Thursday, January 30, 2025 9:1

COPENHAGEN, Denmark & PALO ALTO, Calif.–(BUSINESS WIRE)–Glooko and Hedia launched their interoperable solution, combining connected care, remote patient monitoring, and digital therapeutics for diabetes.

LEIDEN, Netherlands–(BUSINESS WIRE)– #Adults–Azafaros B.V. today announced that its lead asset, nizubaglustat, has been granted orphan drug designation from regulatory authorities in both the United States and the European Union for the treatment of GM1 gangliosidosis. Additionally, the company’s Clinical Trial Application (CTA) for two global Phase 3 studies investigating the drug’s efficacy and safety in GM1/GM2 gangliosidoses and Niemann-Pick Type C (NPC) was approved by multiple European countries